Observational population-based study suggests that continuing statin therapy after the age of 75 years may reduce CV risk in persons taking the medication for primary prevention.

EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

Based on a large Dutch primary care database, lipid-lowering treatment declined with increasing age in subjects aged ≥70 years, with higher prescription in frail vs. non-frail older adults regardless of CVD at baseline.

EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

EAS 2019 An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

EAS 2019 A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

EAS 2019 A fixed combination of bempedoic acid and ezetimibe lowered LDL-c at 12 weeks more than with the individual components, in high-risk patients not at LDL-c goal.

EAS 2019 Børge Nordestgaard made the case for remnant cholesterol and TG, because of the known links of high levels with heart attack, ischemic stroke and death, more so than high LDL-c.

In a primary care patient cohort, >50% of patients initiating statin therapy did not show optimal LDL-c lowering, which significantly increased their risk of future CVD events.

A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.